Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cervical Cancer
Expression and prognostic significance of Fas ligand and bcl-2 evaluated
July 28th, 2005
Researchers studied the expression and prognostic significance of Fas ligand (FasL) and bcl-2 in cervical carcinoma. "Apoptosis-related factors are known to influence survival with many malignant tumors. We performed immunohistochemical analysis of FasL and bcl-2 in invasive cervical cancer to determine the association with prognosis," investigators in Japan reported. "In 125 patients with cervical cancer, 93 cases (74.4%) were positive for FasL, and 94 cases (75.2%) were positive for bcl-2. When 101 cases, clinical stages I through IV, were analyzed by univariate analysis, negative bcl-2 (p=.035) and combined positive FasL and negative bcl-2 (PFNB;...
Source: Women's Health Weekly (2005-07-28)
|
